Product news

Share this article:
The FDA has approved Eli Lilly's Cymbalta (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder. The approval makes Cymbalta the first serotonin-norepinephrine reuptake inhibitor approved for reducing pain in patients with fibromyalgia. 

Allergan said the FDA has approved Trivaris (triamcinolone acetonide injectable suspension), a synthetic glucocorticoid corticosteroid with anti-inflammatory action to treat sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.